scispace - formally typeset
S

Seyedeh Hoda Alavizadeh

Researcher at Mashhad University of Medical Sciences

Publications -  32
Citations -  865

Seyedeh Hoda Alavizadeh is an academic researcher from Mashhad University of Medical Sciences. The author has contributed to research in topics: Liposome & Medicine. The author has an hindex of 13, co-authored 26 publications receiving 626 citations.

Papers
More filters
Journal ArticleDOI

Bioactivity assessment and toxicity of crocin: A comprehensive review

TL;DR: A comprehensive and updated report of empirical investigations on bioactivities and biological characteristics of crocin is provided in this paper, where it is also worth noting that the crocin principle of saffron exhibited high efficacy along with no major toxicity in experimental models.
Journal ArticleDOI

Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids.

TL;DR: In vivo study in BALB/c mice showed improved pharmacokinetic parameters including maximum plasma concentration (Cmax) and time to reach the maximum concentration (Tmax) with nanomicelles as compared to free curcuminoids and two other commercial products.
Journal ArticleDOI

Redox-sensitive nanoscale drug delivery systems for cancer treatment

TL;DR: The aim of the current review is to emphasize the requirements for developing various NDDSs including liposomes, polymeric nanoparticles, micelles, mesoporous silica nanoparticle, nanogels and prodrugs, capable of responding to TME using their Redox-sensitive moieties.
Journal ArticleDOI

Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA)

TL;DR: The results indicated that simple DOTAP nanoliposome containing 1μg/μl SLA are appropriate delivery systems to induce a Th1 type of immune response and protection against L. major infection in BALB/c mice.
Journal ArticleDOI

Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models

TL;DR: Affibody-targeting endowed cisplatin liposomes with significantly enhanced, albeit modest, therapeutic activity in HER2-overexpressing tumor model; however, further values are yet to be determined to advance clinical translation of these targeted nanoparticulates.